Shares of Zafgen Inc. (NASDAQ:ZFGN) saw unusually-strong trading volume on Tuesday . Approximately 521,596 shares traded hands during mid-day trading, an increase of 49% from the previous session’s volume of 350,912 shares.The stock last traded at $6.75 and had previously closed at $6.68.

Several equities research analysts recently commented on ZFGN shares. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research note on Thursday, May 12th. FBR & Co reissued a “buy” rating and issued a $20.00 price target on shares of Zafgen in a research note on Monday, April 4th. Royal Bank Of Canada reissued an “outperform” rating and issued a $19.00 price target on shares of Zafgen in a research note on Tuesday, April 5th. Finally, Leerink Swann restated a “hold” rating and issued a $6.00 target price on shares of Zafgen in a report on Monday, April 11th. Four investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $11.94.

The company has a 50-day moving average price of $6.43 and a 200 day moving average price of $6.58. The firm’s market capitalization is $184.09 million.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. During the same period last year, the business posted ($0.53) EPS. Equities research analysts anticipate that Zafgen Inc. will post ($2.81) EPS for the current year.

A hedge fund recently bought a new stake in Zafgen stock. Oxford Asset Management purchased a new position in Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned approximately 0.87% of Zafgen as of its most recent SEC filing.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.